Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease

J Infect Dis. 1996 Jan;173(1):256-8. doi: 10.1093/infdis/173.1.256.


Thirty-nine previously treated Hodgkin's disease (HD) patients were immunized with 7-valent pneumococcal conjugate vaccine (7-OMPC) followed by one dose of 23-valent polysaccharide pneumococcal vaccine (23-PS). To determine the priming effect of 7-OMPC vaccine, their antibody responses to six serotypes contained in both vaccines were compared to those of 57 HD patients who received 23-PS vaccine only. The geometric mean antibody concentrations after immunization with 23-PS vaccine were significantly higher for five of the six measured serotypes in HD patients primed with 7-OMPC vaccine compared with responses in HD patients who received 23-PS vaccine only. The mean of the six antibody concentrations was significantly higher for the primed group at 12.5 micrograms/mL and 7.76 micrograms/mL, respectively (P = .015). Priming with a conjugate vaccine should be considered as a strategy to protect high-risk adults.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Viral / biosynthesis*
  • Bacterial Capsules / immunology
  • Bacterial Vaccines / immunology*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Hodgkin Disease / immunology
  • Hodgkin Disease / therapy*
  • Humans
  • Immunization
  • Immunoglobulin G / analysis
  • Male
  • Middle Aged
  • Pneumococcal Infections / prevention & control*
  • Pneumococcal Vaccines
  • Polysaccharides, Bacterial / immunology
  • Random Allocation
  • Serotyping
  • Streptococcus pneumoniae / immunology*
  • Vaccines, Conjugate / immunology


  • Antibodies, Viral
  • Bacterial Vaccines
  • Immunoglobulin G
  • Pneumococcal Vaccines
  • Polysaccharides, Bacterial
  • Vaccines, Conjugate